ABBV-514
- Generic Name
- ABBV-514
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 268
- Registration Number
- NCT05005403
- Locations
- 🇺🇸
University of Illinois at Chicago /ID# 251750, Chicago, Illinois, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne, Indiana, United States
🇺🇸Community Health Network, Inc. /ID# 243011, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath